Stem cell therapies for chronic obstructive pulmonary disease: mapping the global clinical trial landscape
4 affiliations
- 1Department of Geriatric Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
- 2Department of Neurorehabilitation, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325000, China.
- 3The Second Clinical Medical College, Wenzhou Medical University, Wenzhou 325000, China.
- 4Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Abstract
Background
Stem cell therapies have emerged as a promising strategy for repairing structural damage and modulating inflammation in chronic obstructive pulmonary disease (COPD). However, a comprehensive characterization of the global clinical trial landscape remains lacking.Methods
We retrospectively analyzed clinical trials of stem cell therapy for COPD registered in the Trialtrove database up to October 1, 2025, supplemented by cross-referencing with ClinicalTrials.gov. Key trial characteristics were independently extracted and cross-checked by 2 investigators.Results
A total of 43 eligible trials were identified. Early-phase studies (Phase I-II) accounted for over 80% of all trials. Mesenchymal stromal cell (MSC)-based therapies and mixed cell populations each accounted for 34.9% of registered trials, followed by bronchial basal progenitor cell-based therapies (23.3%). Among 25 completed trials, only 11 publicly disclosed results. Available findings indicated no major short-term safety concerns for the specific cell products evaluated, whereas efficacy outcomes remained heterogeneous. Academic institutions sponsored most trials, while industry-sponsored studies showed a higher proportion of terminated or inactive trials. The United States and China accounted for the largest numbers of registered trials, although Brazil contributed the greatest number of publicly available outcome reports.Conclusions
Stem cell therapy for COPD remains in an early exploratory stage, with low result-disclosure rates and limited late-phase evidence. Standardized trial design, improved data transparency, and large-scale randomized controlled trials are urgently needed to advance clinical translation.
Related
- Influence of genetic variants on the response to long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) and combination therapies in patients with chronic obstructive pulmonary disease (COPD): a systematic review
- Effective Connectivity and Clinical Correlates in Chronic Obstructive Pulmonary Disease.
- Development of a database for investigating characteristics and quality of published clinical trials in chronic obstructive pulmonary disease: design, implementation, and application
- Non-Coding RNA Regulates Pyroptosis in Chronic Obstructive Pulmonary Disease
- Sleep Quality and Daytime Sleepiness in Patients with Chronic Obstructive Pulmonary Disease in a Tertiary Care Hospital: An Observational Study
BibTeX
@article{xu2026stem,
title = {{Stem cell therapies for chronic obstructive pulmonary disease: mapping the global clinical trial landscape}},
author = {Tingting Xu and Wei Dai and Ziteng Zhu and Yuanrong Dai and Chan Chen and Xiangting Ge},
journal = {Stem cells translational medicine},
year = {2026},
month = oct,
doi = {10.1093/stcltm/szag087},
url = {https://europepmc.org/article/PMC/PMC13726808},
note = {CC BY},
}
RIS
TY - JOUR
TI - Stem cell therapies for chronic obstructive pulmonary disease: mapping the global clinical trial landscape
AU - Tingting Xu
AU - Wei Dai
AU - Ziteng Zhu
AU - Yuanrong Dai
AU - Chan Chen
AU - Xiangting Ge
PY - 2026
DA - 2026/10/01
JO - Stem cells translational medicine
DO - 10.1093/stcltm/szag087
UR - https://europepmc.org/article/PMC/PMC13726808
AB - Background Stem cell therapies have emerged as a promising strategy for repairing structural damage and modulating inflammation in chronic obstructive pulmonary disease (COPD). However, a comprehensive characterization of the global clinical trial landscape remains lacking.Methods We retrospectively analyzed clinical trials of stem cell therapy for COPD registered in the Trialtrove database up to October 1, 2025, supplemented by cross-referencing with ClinicalTrials.gov. Key trial characteristics were independently extracted and cross-checked by 2 investigators.Results A total of 43 eligible trials were identified. Early-phase studies (Phase I-II) accounted for over 80% of all trials. Mesenchymal stromal cell (MSC)-based therapies and mixed cell populations each accounted for 34.9% of registered trials, followed by bronchial basal progenitor cell-based therapies (23.3%). Among 25 completed trials, only 11 publicly disclosed results. Available findings indicated no major short-term safety concerns for the specific cell products evaluated, whereas efficacy outcomes remained heterogeneous. Academic institutions sponsored most trials, while industry-sponsored studies showed a higher proportion of terminated or inactive trials. The United States and China accounted for the largest numbers of registered trials, although Brazil contributed the greatest number of publicly available outcome reports.Conclusions Stem cell therapy for COPD remains in an early exploratory stage, with low result-disclosure rates and limited late-phase evidence. Standardized trial design, improved data transparency, and large-scale randomized controlled trials are urgently needed to advance clinical translation.
SN - 2157-6564
SN - 2157-6580
ER -